<DOC>
	<DOCNO>NCT01634984</DOCNO>
	<brief_summary>Selected 400 case woman primary breast cancer treat operation randomly , detect expression CDK5RAP2 cancer tissue . At time randomly select 100 woman primary breast cancer neoadjuvant chemotherapy . Detect expression CDK5RAP2 neoadjuvant chemotherapy .</brief_summary>
	<brief_title>The Diagnostic Technology Applied Research CDK5RAP2 Breast Cancer</brief_title>
	<detailed_description>The investigator select 400 case woman primary breast cancer treat operation randomly , detect expression CDK5RAP2 cancer tissue . At time randomly select 100 woman primary breast cancer neoadjuvant chemotherapy . Detect expression CDK5RAP2 neoadjuvant chemotherapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Provision inform consent 2 . Pathological confirmation breast cancer 3 . Tumor stage ( TNM ) : T24bN03M0 4 . ER ( + ) and/or PR ( + ) . 5 . Premenopausal woman . 6 . Age≥40 year 7 . Measurable disease per RECIST criterion 8 . Karnofsky≥70 9 . Laboratory criterion : PLT≥100*109/L WBC≥4000/mm3 HGB≥10g/dl ALT AST &lt; 2*ULN 1 . Presence metastatic disease . 2 . Inflammatory breast cancer . 3 . Bilateral breast cancer . 4. previous chemotherapy hormonal therapy current breast neoplasm . 5. malignant tumor ( concurrent previous ) . 6 . Pregnant woman . 7 . Hypersensitive drug CEF regimen ingredient Zoladex . 8 . Any severe systemic disease contraindicate chemotherapy .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>expression CDK5RAP2</keyword>
</DOC>